Ionis Pharmaceuticals, Inc. (IONS) Financial Statements

Ionis Pharmaceuticals, Inc.

IONS · NASDAQ-GS

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total Revenue	$943.71M	$705.14M	$787.65M	$587.37M	$810.46M	$729.26M	$1.12B	$599.67M
Cost of Revenue	$15.91M	$11.21M	$9.13M	$14.12M	$10.84M	$11.95M	$4.38M	$1.82M
Research & Development	$915.62M	$901.53M	$899.63M	—	$638.20M	$531.00M	$461.50M	$411.90M
Selling, General & Administrative	$393.87M	$267.47M	$232.62M	$150.29M	$186.35M	$354.32M	$286.64M	$244.62M
Operating Expenses	$1.33B	$1.18B	$1.14B	$997.56M	$840.64M	$901.35M	$756.72M	$661.05M
Operating Income	-$381.68M	-$475.08M	-$353.73M	-$410.19M	-$30.19M	-$172.08M	$365.88M	-$61.37M
Interest Expense	$17.26M	$16.99M	$12.66M	$8.12M	$9.35M	$9.51M	$12.44M	$44.79M
Other Income / (Expense)	-$15.36M	$1.33M	$14.10M	-$7.27M	-$9.76M	-$62.00K	-$686.00K	-$182.00K
Income Before Taxes	-$379.60M	-$460.07M	-$333.96M	-$257.99M	-$29.15M	-$134.55M	$338.77M	-$76.16M
Provision for Income Taxes	$1.79M	-$6.17M	$32.32M	$11.74M	-$551.00K	$345.19M	$51.51M	-$291.14M
Net Income	-$381.39M	-$453.90M	-$366.29M	-$269.72M	-$28.60M	-$444.26M	$278.14M	$273.74M
Basic EPS	-$2.38	-$3.04	-$2.56	-$1.90	-$0.20	-$3.18	$2.00	$2.09
Diluted EPS	-$2.38	-$3.04	-$2.56	-$1.90	-$0.20	-$3.18	$1.90	$2.07
Basic Shares Outstanding	160.01M	149.51M	143.19M	141.85M	141.02M	139.61M	140.00M	132.32M
Diluted Shares Outstanding	160.01M	149.51M	143.19M	141.85M	141.02M	139.61M	153.16M	134.06M

Analyst Estimates

Period	Consensus EPS	Low	High	Estimates	Revisions
Dec 2026	-$3.62	-$4.11	-$3.21	10	↑0 ↓1
Dec 2027	-$2.45	-$3.34	-$1.25	10	↑1 ↓1
Dec 2028	-$0.29	-$2.67	$1.04	6	↑0 ↓1
Dec 2029	$2.86	$0.73	$5.45	4	↑0 ↓1

Forward estimates are the sell-side consensus reported by Nasdaq, not a metir forecast.

Symbol: IONS
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: NASDAQ-GS

For more than three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.

Key Issues

Bullish view

TipRanks reports 18 analysts with an average 12-month target of $90.13 and a high target of $115, indicating that published expectations remain materially above the $58.09 prior close.

Bearish view

HC Wainwright reduced its target from $115 to $100 and the shares opened at $52.15 after the downgrade, showing that at least one analyst became less constructive and that sentiment is sensitive to valuation or outlook changes.

Analyst Consensus

See all

Buy

20 analysts

$43

Current

—

Low

$85

Average

—

High

Average target implies +98.26% versus the current price.

Earnings History

BeatMissNo estimate

Ionis Pharmaceuticals, Inc.

Analyst Estimates

Peers